Form 4: Olema Director Sells 10,000 Shares Under 10b5-1 Plan

Olema Pharmaceuticals Director Cyrus Harmon sold 10,000 shares of common stock for $26.88 per share under a pre-arranged trading plan.

Summary

• Cyrus Harmon, a Director of Olema Pharmaceuticals, Inc. (OLMA), reported a sale of common stock.
• The transaction involved 10,000 shares of common stock and occurred on January 20, 2026.
• The shares were sold at a weighted average price of $26.88 per share, with prices ranging from $26.85 to $26.96.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction.
• Following the transaction, Cyrus Harmon directly beneficially owns 727,770 shares of common stock.
• Harmon also indirectly beneficially owns 117,028 shares through the Harmon Family Investors LLC, where he serves as the manager.

Sentiment

Score: 5

Explanation: The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a scheduled transaction for diversification or liquidity rather than a reaction to new information about the company's performance or outlook. Therefore, the sentiment is neutral.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is an insider transaction report and does not provide information related to broader industry trends or competitive landscape.

Key Dates

Recommendation

The Form 4 filing reports a pre-scheduled sale of shares by a director under a Rule 10b5-1 plan. This type of transaction is generally considered a neutral event as it reflects personal financial planning rather than a change in the director's outlook on the company's future performance. It does not provide new information that would warrant a change in investment recommendation.

Keywords

Olema Pharmaceuticals, OLMA, Cyrus Harmon, Director, Insider Trading, Stock Sale, Form 4, 10b5-1 Plan, Equity Transaction